Background/Aim: A mainstay of laboratory research into new therapies for sepsis has been the cecal ligation and puncture (CLP) model in rodents. Previous data indicate that the number of punctures made in the cecum and needle size utilized are primary determinants of mortality. Despite this, variability exists in mortality from this model, even when needle size is held constant. The aim of the present study was to evaluate the influence of the length of cecum ligated, independent of needle size, as a determinant of mortality. Materials and Methods: We evaluated this by ligating various cecal lengths in male Sprague-Dawley rats. A double puncture was then made with a 20-gauge needle, and mortality was analyzed. Plasma TNF-α and IL-6 expression was assessed at 6 h. Animals received no antibiotics, were not fasted, and fluid resuscitation was administered. Results: We determined that mortality does not begin to occur until a distance of >5% of cecal length is ligated. Further, our findings indicate that in this model, 90–100% mortality occurs 4 days following CLP when a distance of >30% is ligated. TNF-α and IL-6 expression is markedly increased with increasing length of cecum ligated. Conclusions: Our data demonstrate that the length of cecum ligated is a major determinant of mortality in the CLP model of sepsis. These findings indicate that investigators must rigorously control the distance of the cecum ligated in order to generate consistent mortality and inflammation data when utilizing the CLP model in rats. Further, the mortality from this model can be adjusted to fit the individual needs of a particular experiment.

Wichterman KA, Baue AE, Chaudry IH: Sepsis and shock – A review of laboratory models and a proposal. J Surg Res 1980;29:189–201.
Sam AD, Sharma AC, Law WR, Ferguson JL: Splanchnic vascular control during sepsis and endotoxemia. Front Biosci 1997;2:72–92.
Deitch E: Animal models of sepsis and shock: A review and lessons learned. Shock 1998;9:1–11.
Chen J, Raj N, Kim P, Andrejko KM, Deutschman CS: Intrahepatic nuclear factor-kappa B activity and α1-acid glycoprotein transcription do not predict outcome after cecal ligation and puncture in the rat. Crit Care Med 2001;29:589–596.
Kong CW, Tsai K, Chin JH, Chan WL, Hong CY: Magnolol attenuates peroxidative damage and improves survival of rats with sepsis. Shock 2000;13:24–28.
Otero-Anton E, Gonzalez-Quintela A, Lopez-Soto A, Lopez-Ben S, Llovo J, Perez LF: Cecal ligation and puncture as a model of sepsis in the rat: Influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor α levels. Eur Surg Res 2001;33:77–79.
Lundblad R, Sandven P, Giercksky KE: The physical nature of a large bowel perforation predicts severity of the subsequent inflammatory response. Shock 1995;3:455–461.
Zamir O, Hasselgren PO, Kunkel SL, Frederick J, Higashiguchi T, Fischer JE: Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch Surg 1992;127:170–174.
Lundblad R, Ekstrom P, Giercksky KE: Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995;3:210–215.
Yang S, Koo DJ, Chaudry IH, Wang P: Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality. Crit Care Med 2001;29:1201–1206.
McCuskey RS, Nishida J, McDonnell D, Baker GL, Urbaschek R, Urbaschek B: Effect of immunoglobulin G on the hepatic microvascular inflammatory response during sepsis. Shock 1996;5:28–33.
Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002;17:463–467.
Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Guo RF, Padgaonkar VA, Younkin EM, Laudes IJ, Riedemann NC, Younger JG, Ward PA: Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001;15:568–570.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.